Introduction
Osteopetrosis is a genetically heterogeneous disease characterized by defective bone resorption, increased bone density, and skeletal fragility. Several types of osteopetrosis have been described and most are autosomal recessive [1] . An autosomal dominant form of osteopetrosis, also known as Albers-Schönberg disease, occurs in ~ 1:20,000 persons [2, 3] .
Symptoms and signs of Albers-Schönberg disease generally appear in childhood or adolescence, and there is wide phenotypic variability within and across families. The phenotype in persons with Albers-Schönberg disease can cause debilitating problems and worsen over time, and no beneficial pharmacological therapy is currently available [3] [4] [5] .
Albers-Schönberg disease is caused by dominant negative (i.e., antimorphic) mutations in CLCN7, the gene encoding the homodimeric chloride channel 7 (CLC-7). This channel functions as a slow voltage-gated 2Cl -/1H + exchanger [6, 7] , and gating depends on conformational changes that are communicated from one subunit to the other in the dimer [8] .
In osteoclasts, CLC-7 dimers transport chloride ions into the resorption lacunae. Complete deficiency of CLC-7 causes a severe form of autosomal recessive ostepetrosis by making osteoclasts unable to resorb bone. Heterozygous CLCN7 mutations that produce a mutant protein, which interferes with the function of wildtype protein, cause Albers-Schönberg disease. More than 25 different heterozygous mutations that cause Albers-Schönberg disease have been identified [9] .
In 2014, Alam et al [10] described mice with a Clcn7 knockin allele (Clcn7 G213R ), which is the most common mutation reported in patients with Albers-Schönberg disease [11] . Mice homozygous for Clcn7 G213R had a severe osteopetrotic phenotype and died weeks after birth, whereas heterozygous mice (i.e., Clcn7 G213R/+ ) had a phenotype that resembled AlbersSchönberg disease, including increased areal BMD, increased BV/TV, and increased osteoclast numbers with reduced activity [10] . When the mutant allele was crossed into
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4 different genetic backgrounds, the highest percent increase in BV/TV compared to controls was found with the 129S1 background, followed by DBA/D2, C57BL/6J and Balb/c backgrounds [12] . Since interferon gamma (IFN-G) has been reported to benefit some patients with recessive forms of osteopetrosis [13] , this therapy was evaluated in Clcn7 G213R/+ mice. Thrice weekly IFN-G injection in Clcn7 G213R/+ mice on the 129S1
background, from 4 to 12 weeks of age, significantly reduced trabecular bone BV/TV; one reason for this improvement seemed to be improved osteoclast function as indicated by increase in the serum CTX/TRAPc5b ratio [14] .
We created mice with a different osteopetrosis-associated Clcn7 knockin mutation (Clcn7
F318L
). Here we describe the phenotype of mice with Clcn7 F318L alleles and their response to IFN-G therapy.
Methods
The Institutional Animal Care and Use Committee at Boston Children's Hospital approved this work. All experiments were conducted in accordance with the National Institutes of arm: P3-CCCTTAGGAACTTCGCATAGTTAGC, P4-CTGGAGTGGGTAGGACAT). The targeting arms along with the p.F318L mutation containing fragment, were combined by infusion cloning (Clontech, CA, USA) with a floxed neomycin selection cassette and a thymidine kinase selection cassette to produce the targeting vector depicted in Figure 1A .
Homologous recombination of the linearized construct was performed in JM8A3.N1 ES cells
[15] using ganciclovir and neomycin selection. Correctly targeted ES cells were identified by long-range PCR across both homology arms (5'end: P5-GAGCAGGAGTTACAGCTGGG, P6-GCTCGACTAGAGCTTGCGGA; 3'end: P7-CCACTTGTGTAGCGCCAAG; P8-TCCCCACACACCTACTGACA). A correctly targeted clone with a normal karyotype was introduced into C57BL/6J blastocysts to produce chimeric mice, which were then crossed to C57BL/6J mice to attain germline transmission of the p.F318L mutation. Tg(Gata1-cre)1Sho [16] mice were then used to Cre-excise the neomycin selection cassette. The final Clcn7
F318L
allele used in these studies is depicted in Figure 1A .
Animal breeding, maintenance, and genotyping

Clcn7
F318L/+ mice were intercrossed, crossed with C57BL/6J mice, or crossed with Clcn7 G213R/+ mice [10] . Offspring were tail clipped at 10 days of age, weaned before 28 days of age and then housed with same-sex littermates. Tail snip DNA was recovered using the HotSHOT method [17] . For genotyping the Clcn7 F318L allele, PCR primers (P9:
GCTCCTCAGACGCATGGAAT and P10: AGAAAACAGGAGAGCTGGCA), which generate a 407 bp amplimer for the wildtype allele and a 530 bp amplimer for the Clcn7 F318L allele ( Figure 1B ) were used. Clcn7 G213R genotyping was performed as previously described
[10].
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Phenotypic assessment
Twenty-one day old mice were sacrificed using CO 2 followed by cervical dislocation.
Prior to sacrifice, animals were weighed and bone mineral density (BMD) was measured with the Piximus II dual energy X-ray absorptiometer (GE Lunar, Madison, WI). After sacrifice, femurs and 4 th lumbar vertebra were removed, dissected free of soft tissue, and either placed in 4% paraformaldehyde (PFA) at room temperature for micro-computed tomography (CT) and histomorphometry analysis or wrapped in saline soaked gauze and frozen at -20°C for biomechanical measurements.
Twelve-week-old mice, which had received intraperitoneal (IP) Calcein (Sigma, MO, USA; 10mg/Kg) when 11-weeks-old, and IP Alizarin complexone (Sigma, MO, USA; 20mg/Kg) when 11-weeks and 4-days old as previously described [18] , were fasted for 6 hours prior to sacrifice. Prior to euthanasia by CO 2 and cervical dislocation, the animals were weighed and had their BMD measured. After euthanasia, cardiac puncture was performed to collect blood for serum markers of bone anabolism and catabolism. Femora and 4 th lumbar vertebrae were removed and processed as described earlier.
IFN-G treatment
Wild type (i.e., Clcn7 +/+ ) and mutant (i.e., Clcn7 F318L/+ and/or Clcn7 g/kg/dose of a 10 µg/ml stock solution). When therapy began at P10, injections were given 5 times/week until P22 (10 doses total). Mice were then sacrificed. When therapy began at 4
weeks of age, injections were given 3 times/week until 12 weeks of age. Mice were then sacrificed.
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BMD measurements
Whole body scanning was performed using a Piximus II dual energy X-ray absorptiometer (GE Lunar, Madison, WI) with 0.18mm x 0.18mm resolution. The machine was calibrated before each scanning session using a phantom supplied by the manufacturer. The scan was performed with the mice in a prone position under 2.5% isoflurane (Baxter, IL, USA) anesthesia, with each limb spread on a plastic tray. Measurements of BMD (g/cm 2 ) and bone mineral content (BMC, g) were obtained from the whole-body data after excluding the calvarium, mandible and teeth.
CT measurements
Femoral midshaft cortical bone, distal femur trabecular bone, and 4 th lumbar vertebra were scanned on a Scanco CT-35 specimen scanner (Scanco Medical AG, Switzerland) as previously described [19, 20] . Briefly, the tomography parameters used were as follows: 50 
Histomorphometry measurements
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At the time of sacrifice, femurs were collected from 7-10 male 12-week-old Clcn7 +/+ , Clcn7 F318L/+ and IFN-G treated Clcn7 F318L/+ mice for histomorphometric analysis. Osteoblast and osteoclast numbers and density, and dynamic bone formation parameters, were measured using standard procedures recommended by the American Society of Bone and Mineral
Research (ASBMR) histomorphometry committee [22] .
Three-point bending test
Femur biomechanical studies were performed as previously described [19, 20] Ten 8-week-old female C57BL/6J mice were randomized to receive a single subcutaneous injection of either vehicle or mouse IFN-G (37.5 µg/kg). Two hours later the animals were
euthanized by CO 2 , blood was collected by cardiac puncture, and serum separated as described above. Serum concentration of mouse IFN-G was measured using the Quantikine IFN-gamma ELISA kit (kit number MIF00; R&D Systems, MN, USA).
Statistical analyses
Statistical analyses were performed using SPSS Statistics 23.0 (IBM). Continuous variables were expressed as mean ± 1 standard deviation (±1SD). Multiple groups were compared using analysis of variance (ANOVA) test followed by Bonferroni's multiple comparison test. Statistical significance was considered when p-values were ≤ 0.05. ) that fail to produce protein [23] .
Results
The
Therefore, to determine whether the Clcn7 F318L knockin allele is capable of producing a mutant protein, we performed 3 different assays. First, we used RT-PCR with a primer-pair anchored 5 exons upstream of the intron with the residual loxP site and 2 exons downstream of the missense mutation containing exon to determine if the Clcn7 F318L allele is spliced normally. We observed the same sized RT-PCR product in wildtype, heterozygous, and homozygous mice, consistent with the knockin allele having normal mRNA splicing ( Figure   1D ). Second, we quantified the amount of wildtype and mutant transcript expressed in
heterozygous mice using droplet digital PCR. We observed equal numbers of wildtype and mutant transcripts in cDNA from bone ( Figure 1E ), kidney and liver (data not shown). Third, we used an anti-CLC-7 antibody to detect protein in cultured bone marrow cells. We observed similar immunofluorescence in cells from Clcn7 +/+ and Clcn7 F318L/F318L mice ( Figure   1F ). Taken together, these data indicate that the Clcn7 F318L allele is normally expressed and translated into protein. Therefore, mutant protein is produced but is non-functional.
We next crossed Clcn7 F318L/+ mice with Clcn7 G213R/+ mice and generated compound heterozygous offspring to determine if the two mutant proteins could complement each other.
Clcn7
F318L/G213R mice lack tooth eruption, are runted, and die by ~ 1 month of age (data not shown), just like the Clcn7 F318L/F318L mice. Therefore, there is no evidence of complementation.
We next turned our attention to Clcn7 F318L/+ mice. When examined at 12 weeks of age, we found a slight increase in BMD in males Clcn7 F318L/+ mice compared to Clcn7 +/+ mice. The most significant CT differences we observed in male and female Clcn7 F318L/+ mice compared to Clcn7 +/+ mice were in trabecular bone (measured both in the femur ( Figure 2) and vertebra (data not shown)). Only male Clcn7 F318L/+ mice showed differences for cortical bone parameters and three-point bending assays of bone strength when compared to Clcn7 +/+ mice ( Figure 2 
by DEXA (p<0.05, Figure 3 ). No significant differences were observed between 3-week-old We also administered IFN-G to Clcn7 F318L/F318L mice beginning when they were 11 days of age. However, rather than benefitting these animals, we observed that these mice died before the protocol could be completed, whereas vehicle treated mice did not.
F318L/+ mice have increased osteoclast number, which is reduced by interferongamma therapy.
per bone perimeter and surface area in Clcn7 F318L/+ mice compared to Clcn7 +/+ mice.
Consistent with this observation both Clcn7
F318L/+ male and female mice had increased serum TRAPc5b compared to Clcn7 +/+ littermates.
Decreased numbers of osteoclasts per bone perimeter and per surface area were observed, as was decreased serum TRAcP5b, in IFN-G treated Clcn7 F318L/+ mice compared to vehicle treated Clcn7 F318L/+ mice ( Figure 5 ). However, the IFN-G effect on osteoclasts was not associated with a change in trabecular bone BV/TV (Figure 4 ), perhaps because IFN-G treatment also modestly lowered BFR/BV in Clcn7 F318L/+ mice ( Figure 5 ).
Discussion
Here we describe a second mouse model of Albers-Schönberg disease. More than 25 different causal mutations have been identified in patients and ex vivo studies suggest that mutations may negatively impact CLC-7 channel function via different mechanisms [6] .
Consequently, having more than one animal model makes it possible to ask whether an intervention that is beneficial for one mutation could have broad benefit.
The use of an allelic spectrum of disease-causing mutations when searching for diseasemodifying drugs has already been demonstrated for other diseases, such as osteogenesis imperfecta [18, [24] [25] [26] [27] [28] [29] [30] and cystic fibrosis [31] . Six classes of mutations have been reported in the gene responsible for causing cystic fibrosis based on the effect of the mutation of protein synthesis, trafficking, and function [31] . In the case of cystic fibrosis, which is associated with thousands of different disease-causing mutations in CFTR, drugs that significantly help patients with one class of mutations may be ineffective in patients with other classes. Here, +/-) mutation [23] .
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Consistent with a previous report that used IFN-G in the Clcn7
G213R/+ mouse model [14] we found that IFN-G increased the CTX/TRAcP5b ratio, suggesting osteoclast function improves. Quantitative histomorphometry was not performed in the Clcn7 G213R/+ mouse IFN-G study, although an increase in osteoclast number was observed when this mouse model was first described and has also been reported in patients with Albers-Schönberg disease [10, 32] .
Histomorphometric analyses in our Clcn7 F318L/+ mice also revealed an increased number of osteoclasts, that decreased in response to IFN-G treatment, consistent with the reduction in serum TRAcP5b levels. However, in contrast to Clcn7 G213R/+ mice, IFN-G did not increase CTX-I levels in Clcn7 F318L/+ mice, nor did it normalize BV/TV. Thus, the putative effect of IFN-G on osteoclast function in Clcn7 F318L/+ mice is lower than that in Clcn7 G213R/+ mice.
The difference in the effectiveness of IFN-G in Clcn7 F318L/+ versus Clcn7 G213R/+ mice may be explained by differences in how these two mutations impact CLC-7 trafficking and function. Cell transfection studies expressing mutant CLC-7 proteins indicate that some missense mutations cause retention of protein in the endoplasmic reticulum (ER) [6, 33] , whereas other missense mutations do not affect localization but change channel activity [6] .
A C C E P T E D M A N U S C R I P T 16
Cells expressing the p.G213R mutant CLC-7, retain the mutant protein in the endoplasmic reticulum [6, 33] . In contrast, cells expressing p.F318L mutant CLC-7 can transport the mutant protein to the lysosomal membrane where it is unable to produce plasma membrane current, suggesting that this mutation interferes with ion transport but not protein trafficking [6] . Thus, if IFN-G worked by improving CLC-7 channel trafficking in osteoclasts, it could benefit Clcn7 +/+ and Clcn7 G213R/+ mice by allowing protein to reach the ruffled membrane more efficiently. In Clcn7 G213R/+ mice, this would reduce the retention of mutant protein in the ER. Since CLC-7 dimers in Clcn7 F318L/+ mice do not appear to have a trafficking problem, IFN-G therapy would not be expected to have the same degree of benefit in these animals.
IFN-G is a cytokine that plays a critical role in both innate and adaptive immune responses, and is produced by natural killer (NK), NK T cells, CD4 and CD8 cells [34] . In 1995 this drug showed some benefit in severe osteopetrosis patients [13] and, in a case report, benefit in a patient with intermediate osteopetrosis [35] . However, whether benefit derives from IFN-G actions on osteoclasts remains uncertain. In vitro studies showed that osteoclasts from patients with osteopetrosis stimulated with IFN-G were larger and had increased TRAP expression [36] . However, when this experiment was performed using control osteoclasts, IFN-G inhibited osteoclast formation and lowered Cathepsin K mRNA expression [37] .
Adding to these puzzling results, IFN-G Receptor 1 knockout mice display an osteoporotic phenotype associated with reduced mineral apposition and bone formation but also reduced markers of osteoclast activity [38] . Moreover, exogenous administration of IFN-G in ovariectomized mice increased BMD and bone strength, rescuing the disease [39] . Thus, the IFN-G effect on bone is not restricted to osteoclasts. Histomorphometric analyses revealed an increased number of osteoclasts in Clcn7 F318L/+ mice compared to wildtype mice, as has been previously reported in the Clcn7 G213R/+ mice and in patients with Albers-Schönberg disease [10, 32] . In Clcn7 F318L/+ mice, IFN-G decreased osteoclast number, which is
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17 consistent with the reduction in serum TRAcP5b levels we observed in treated mice. With respect to bone formation, Clcn7 F318L/+ mice were not significantly different from wildtype mice, similar to what has been reported for Albers-Schönberg disease [40] . Although IFN-G therapy increased the active mineralizing surface in Clcn7 F318L/+ mice, it decreased the mineral apposition rate. Overall there was no effect of IFN-G on bone formation, µCT measurements of BV/TV and the serum measurements of P1NP.
Having a second mouse model with a dominant negative mutation in Clcn7 that impairs osteoclast function makes it possible in a pre-clinical model to understand how drugs that affect CLC-7 trafficking and/or function might affect bone properties in patients with AlbersSchönberg disease.
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